- 著者
-
Yoshito MIYATA
Shin OHTA
Akihiko TANAKA
Kaho AKIMOTO
Hiroki SATO
Tomoki UNO
Haruna SATO
Yoshitaka UCHIDA
Megumi JINNO
Kuniaki HIRAI
Hideki INOUE
Tetsuya HONMA
Mayumi YAMAMOTO
Shintaro SUZUKI
Hironori SAGARA
- 出版者
- The Showa University Society
- 雑誌
- The Showa University Journal of Medical Sciences (ISSN:09156380)
- 巻号頁・発行日
- vol.32, no.4, pp.247-256, 2020 (Released:2021-01-28)
- 参考文献数
- 28
Mepolizumab is a monoclonal antibody against interleukin-5 used for the treatment of severe asthma. The effect of long-term mepolizumab administration and its persistence in clinical practice is poorly understood. Thus, this study aimed to investigate the effect of long-term administration of mepolizumab in patients with severe asthma. Mepolizumab was administered to 20 patients with severe asthma. We then prospectively followed the patients for 104 weeks to investigate the efficacy of long-term mepolizumab administration in clinical practice. Eleven patients were evaluated for 104 weeks. Mepolizumab administration reduced asthma exacerbations in a year from 52 to 104 weeks and improved asthma control in every period as assessed by questionnaires. Also, blood eosinophil counts decreased at every point, and blood basophil counts decreased at 104 weeks. We compared various parameters among the 11 patients who continued administration for more than 104 weeks and 7 patients who discontinued treatment due to ineffectiveness. Significant differences were observed in disease duration, maximum expiratory flow at 50%, and blood basophil count. Long-term mepolizumab administration improved asthma symptoms in patients with severe asthma and reduced the frequency of exacerbations.